See more : Upbest Group Limited (0335.HK) Income Statement Analysis – Financial Results
Complete financial analysis of Cibus, Inc. (CBUS) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Cibus, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Altimar Acquisition Corp. III (ATAQ) Income Statement Analysis – Financial Results
- Scan Inter Public Company Limited (SCN.BK) Income Statement Analysis – Financial Results
- Capital One Financial Corporation (COF) Income Statement Analysis – Financial Results
- Grupo Mateus S.A. (GMAT3.SA) Income Statement Analysis – Financial Results
- DATAGROUP SE (0W19.L) Income Statement Analysis – Financial Results
Cibus, Inc. (CBUS)
About Cibus, Inc.
Cibus, Inc., a agricultural technology company, develops and licenses plant traits to seed companies for royalties. The company primarily focus on trait productivity in two areas, including productivity traits that enable farmers to have higher yields and reduce the use of the crop protection chemicals and fertilizers; and sustainable ingredients that enable corporations to replace ingredients that are fossil fuel based or whose production results in increased greenhouse gases. The company is based in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.82M | 157.00K | 25.99M | 23.85M | 7.30M | 236.00K | 508.00K | 399.00K | 1.27M |
| Cost of Revenue | 395.00K | 1.53M | 28.56M | 35.13M | 9.28M | 1.08M | 551.00K | 200.00K | 751.00K |
| Gross Profit | 1.42M | -1.38M | -2.57M | -11.28M | -1.98M | -845.00K | -43.00K | 199.00K | 521.00K |
| Gross Profit Ratio | 78.26% | -877.07% | -9.89% | -47.28% | -27.19% | -358.05% | -8.46% | 49.87% | 40.96% |
| Research & Development | 42.37M | 11.55M | 11.34M | 11.08M | 12.21M | 9.85M | 11.56M | 5.64M | 2.77M |
| General & Administrative | 0.00 | 0.00 | 0.00 | 16.16M | 18.97M | 18.51M | 14.74M | 6.67M | 3.57M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 4.38M | 5.17M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 28.91M | 10.97M | 15.38M | 20.54M | 24.14M | 18.51M | 14.74M | 6.67M | 3.57M |
| Other Expenses | 249.02M | 5.57M | 19.00K | -126.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 320.31M | 22.53M | 26.76M | 31.87M | 37.69M | 28.35M | 26.30M | 12.31M | 6.34M |
| Cost & Expenses | 320.70M | 22.53M | 55.32M | 67.00M | 46.97M | 28.35M | 26.30M | 12.51M | 7.09M |
| Interest Income | 527.00K | 60.00K | 17.00K | 557.00K | 1.60M | 1.52M | 0.00 | 0.00 | 0.00 |
| Interest Expense | 18.89M | 75.00K | 1.43M | 1.44M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Depreciation & Amortization | 4.69M | 1.53M | 2.34M | 1.87M | 1.61M | 1.08M | 551.00K | 345.00K | 147.00K |
| EBITDA | -314.59M | -15.21M | -25.43M | -41.53M | -36.52M | -25.56M | -25.43M | -11.74M | -5.48M |
| EBITDA Ratio | -17,313.43% | -14,248.41% | -109.75% | -170.19% | -499.81% | -10,810.59% | -4,968.11% | -2,948.37% | -445.52% |
| Operating Income | -318.88M | -22.37M | -29.33M | -43.83M | -39.67M | -28.12M | -25.79M | -12.11M | -5.81M |
| Operating Income Ratio | -17,549.97% | -14,248.41% | -112.87% | -183.77% | -543.76% | -11,913.14% | -5,076.57% | -3,034.84% | -457.08% |
| Total Other Income/Expenses | -18.76M | 5.48M | 133.00K | -1.00M | 61.00K | 218.00K | -191.00K | 23.00K | -75.00K |
| Income Before Tax | -337.64M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Income Before Tax Ratio | -18,582.44% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| Income Tax Expense | -4.00K | -1.45M | -114.00K | 1.56M | 1.49M | 1.26M | 1.00K | 5.00K | 261.00K |
| Net Income | -267.63M | -16.89M | -29.20M | -44.84M | -39.61M | -27.90M | -25.98M | -12.09M | -5.89M |
| Net Income Ratio | -14,729.06% | -10,758.60% | -112.36% | -187.98% | -542.93% | -11,820.76% | -5,114.17% | -3,029.07% | -462.97% |
| EPS | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| EPS Diluted | -25.95 | -18.36 | -38.96 | -66.16 | -60.37 | -45.46 | -56.10 | -22.72 | -11.07 |
| Weighted Avg Shares Out | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
| Weighted Avg Shares Out (Dil) | 10.31M | 919.95K | 749.52K | 677.65K | 656.11K | 613.67K | 463.07K | 532.00K | 532.00K |
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS
NEW YORK , July 24, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS
NEW YORK, NY / ACCESSWIRE / July 23, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ:CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Announces an Investigation on Behalf of Cibus, Inc. (CBUS) Shareholders Who May Have Been Affected by Fraud
NEW YORK, NY / ACCESSWIRE / July 22, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report...
An Investigation Has Commenced on Behalf of Cibus, Inc. Shareholders. Contact Levi & Korsinsky to Discuss your CBUS Losses.
NEW YORK, NY / ACCESSWIRE / July 20, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS
NEW YORK, July 20, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Shareholder Rights Advocates at Levi & Korsinsky Investigate Cibus, Inc. (CBUS) Regarding Possible Securities Fraud Violations
NEW YORK, NY / ACCESSWIRE / July 18, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS
NEW YORK , July 18, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Levi & Korsinsky Reminds Cibus, Inc. Investors of the Ongoing Investigation into Potential Violations of Securities Laws - CBUS
NEW YORK, NY / ACCESSWIRE / July 17, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Cibus, Inc. ("Cibus, Inc.") (NASDAQ:CBUS) concerning possible violations of federal securities laws. Bonitas Research ("Bonitas") issued a report...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS
NEW YORK, NY / ACCESSWIRE / July 14, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. ("Cibus" or the "Company") (NASDAQ:CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cibus, Inc. - CBUS
NEW YORK, July 12, 2024 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Cibus, Inc. (“Cibus” or the “Company”) (NASDAQ: CBUS). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
Source: https://incomestatements.info
Category: Stock Reports